The aim of the SARS-CoV-2-CZ-PREVAL-II Study is to quantify the prevalence of participants with antibodies against SARS-CoV-2 and/or cell immunity against SARS-CoV-2 in specific subjects cohorts.
The aim of the SARS-CoV-2-CZ-PREVAL-II Study is to quantify the prevalence of participants with antibodies against SARS-CoV-2 and/or cell immunity against SARS-CoV-2 in four specific cohorts: participants with chronic illness, healthy volunteers participating in the Study of the Czech Academy of Science, healthcare workers, and healthy volunteers that participated in the "Herd Immunity Study SARS-CoV-2-CZ-Preval" in May 2020. The primary aim of the study is to estimate the number of people with anti-SARS-CoV-2-antibodies, i.e., people with COVID-19 history, or with vaccination against COVID-19. Antibodies test will focus on two main proteins of virus SARS-CoV-2: S-protein and N-protein. The secondary aims of the study are: * quantitative analysis of cellular immunity and the other relevant markers, * estimation of the proportion of participants with asymptomatic COVID-19 infection * quantification of anti-SARS-CoV-2 antibodies and cell immunity according to individual risk factors.
Study Type
OBSERVATIONAL
Enrollment
7,268
The study will evaluate the current presence of infection, specific antibodies at least in the IgG class in blood plasma or serum (antibody tests focusing on two SARS-CoV-2 proteins: S-protein and N-protein).
Quantification of the level of cellular immunity from venous blood collected in approximately 30% of examined individuals.
Institute of Health Information and Statistics of the Czech Republic
Prague, Czechia
Detection of a number of subjects with IgG anti-SARS-CoV-2 antibodies
The primary outcome is to quantify the prevalence of participants with IgG anti-SARS-CoV-2 antibodies in the specified subjects cohorts.
Time frame: September-October 2021
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.